Eurofins Ingenasa is taking part in SaPher project, aiming to develop the antibodies of interest not commercially available in the market for the target allergen industries.

Food allergies affect over 17M people in Europe and increasing at a 2 digit prevalence rate. With no cure, the only successful method to prevent allergic reactions is to strictly avoid all foods containing the allergen.

The current lack of standardized food allergen control plans and cost-effective allergen testing tools drives food manufacturers to adopt over cautious labelling strategies. As a result, 90% of products with ¨may contain¨ allergen labels do not contain any. This reduces the choice of safe food for the allergic population (39.1M people), leading to risk-taking behaviour. SaPher project will disrupt the food allergen assessment market thanks to the development of an allergen assessment procedure supported by the industrialization and commercial deployment of our full automatic SaPher nano-photonics biosensing allergen test platform.

Read more here: https://cordis.europa.eu/project/id/958855

Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

La exposición al frío y al calor duran...

El equipo de investigadores observó cambios en el...

Uso de RNA móviles para mejorar la asim...

El gen AtCDF3 promueve una mayor producción de az...

Destacadas

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

En nuestro post hablamos sobre este interesante tipo de célula del si...

Nuevo avance para desarrollar tratamient...

by Universitat de Barcelona

Los resultados muestran que el adenocarcinoma presenta una angiogénes...

Diapositiva de Fotos